Episode Details

HUTCHMED H1 2026 Preview earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: HOLD (3/5 conviction, MODERATE) - CURRENT @ $10.87 - HOLD - BUY below $9.50 with $8.00 stop - AVOID above $18.00 TRIGGER: SAFFRON Phase III topline readout (window late Q3 2026) WINDOW: Through SAFFRON readout (~3-4 months) TRACKER: chargedalpha.com/track/HCM WALL STREET CONSENSUS - Ratings: 2 Strong Buy / 3 Buy / 6 Hold / 1 Sell / 0 Strong Sell - HOLD - Median 12-month price target: $18.50 (range $12 - $28) - Charged Alpha vs consensus: ALIGNED THESIS FRUZAQLA royalty stream + $1.4B cash floor + binary SAFFRON optionality Bull lever: SAFFRON Phase III hits - savolitinib global label, $200M+ in royalties Key risk: SAFFRON Phase III misses - savolitinib thesis impairment, $200M+ R&D writedown QUALITY CHECK - Management quality grade: B+ (CEO Weiguo Su has led HUTCHMED through the FRUZAQLA US/EU launch and the Takeda global partnership - both validate HUTCHMED's drug-development engine. The Hutchison Sinopharm divestiture cleaned up the cap table and added $415.8M in cash. SAFFRON Phase III outcome is the next test of scientific judgement; the company has been disciplined on R&D allocation.) - Earnings quality grade: C+ (FY2025 GAAP EPS of $2.66 was overwhelmingly driven by a $415.8M one-time Sinopharm divestiture gain. The underlying operating result was a $7M loss with negative op margin. Adjusted EPS of $0.22 missed by a small amount. Investors should treat GAAP as non-recurring; the $0.22 adj is the clean operating read.) CHAPTERS 0:00 Hook 0:10 S0b_Year 0:38 The Print 1:12 S1b_BeatDecomp 1:41 The Trend 2:38 The Segments 3:08 The FCF Bridge 4:02 S4b_MarginQual 4:33 Guidance & The Narrative Diff 5:32 S5b_Catalyst 8:16 Peer Dot-Plot 8:44 S6b_Valuation 9:13 Management & Earnings Quality 10:52 S8a_Call 11:20 S8b_Call KEY METRICS - H1 2026 Preview - Revenue: $n/aB (YoY -15.0%, beat est by +2.5%) - EPS: $2.66 (vs $0.22 est, beat +1109.0%) - Operating margin: n/a% - Free cash flow: $0.09B (15.5% margin) NARRATIVE DIFF - what changed in management tone - Prior call: "FRUZAQLA US launch ramp is the near-term value driver; SAFFRON readout 2026." - This call: "FRUZAQLA +26% in-market YoY; Sinopharm sold; SAFFRON readout this summer." - Tone shift: Revenue +2.5% vs estimate; FRUZAQLA royalties accelerating; SAFFRON timing tightened. DATA SOURCES - FMP (financialmodelingprep.com) - HUTCHMED H1 2026 Preview press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in HCM. Do your own research before any investment decision. #HCM #HUTCHMED #earnings #investing #stocks #ChargedAlpha